banner

Newsletter

Pfizer Launches Competitive Grants Program to Advance Cardiovascular Disease Research

Pfizer Inc. today announced the launch of a new competitive grants program the company is funding to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer’s ongoing commitment to translate scientific discoveries into innovative medicines for patients with cardiovascular disease. Pfizer currently is studying bococizumab, an investigational PCSK9 inhibitor, in a Phase 3 clinical trial program, known as SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events), for its potential to lower low density lipoprotein cholesterol (LDL-C) and improve cardiovascular outcomes.

Cardiovascular disease, the leading cause of death worldwide, remains a global, public health issue despite many advances in treatment. The first annual ASPIRE Cardiovascular competitive grants program will fund multiple grants of up to $100,000 each to support research designed to uncover new insights about the role of the PCSK9 protein/gene in health and disease.

Read the entire press release here.